Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Emerging PAD Devices Impress With New Trial Results, Funding

Executive Summary

Two very different ways to treat peripheral arterial disease – lithotripsy combined with angioplasty and nitinol Tack implants – have demonstrated impressive six-month and one-year clinical results, respectively, and companies with these devices continue to attract funding.

You may also be interested in...



PAD-Focused Medtechs Eye Golden Period In Growing Silver Market

Improving the patient’s QoL and preventing disease progression, and with it the threat of critical limb ischemia and amputation, dominate peripheral artery disease management, but emerging technologies and the aging population are set to boost a percutaneous transluminal angioplasty market that is already worth $730 million in the US alone.

Re-Evaluating Growth Opportunities In Vascular Interventional Device Markets

Manufacturers are finding it harder to innovate in the vascular interventional device arena as market and regulatory pressures take their toll. New coronary drug-eluting stents face a difficult challenge with the high bar now set by existing devices, and there have been several recent disappointments in the areas of renal denervation, drug-coated balloons, and renal artery stenting; still there are areas of opportunity that continue to look promising, with bioresorbable stents offering perhaps the best prospect among vascular therapies for future blockbuster status.

After Atherectomy: Shockwave Medical Preps For Success

An increasing proportion of patients are presenting to cath labs with calcified plaque, and emerging cardiovascular interventions are driving the demand for calcium debulking technologies that are more benign than conventional atherectomy or balloon angioplasty. Shockwave Medical’s novel platform for debulking calcified plaque in vessels is based on lithotripsy, the use of mechanical energy to fracture kidney stones; the start-up believes it has a technology that’s specific for calcium and benign to healthy tissue.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT035920

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel